TORONTO, Nov. 20 /CNW/ - Patheon (TSX:PTI), a global provider of drug
development and manufacturing services to the international pharmaceutical
industry, announced today that it has signed a master service agreement with
Omnicare Clinical Research, a leading global CRO, for distribution of clinical
trial materials in Europe and Asia Pacific.
Under the terms of the agreement, Omnicare Clinical Research's clinical
supplies division will provide Patheon's customers with various clinical
supply services that include monitoring, distribution and return
accountability. The agreement now enables Patheon to provide a broader
clinical materials service to its clients.
Dr. Colin Minchom, Patheon's Vice President for Pharmaceutical
Development Services, North America, stated, "We are excited to expand our
expertise and development and clinical packaging capabilities with assistance
from Omnicare Clinical Research. By leveraging Omnicare Clinical Research's
strengths, we're able to provide Patheon's clients with a greater variety of
manufacturing and packaging options, including distribution locations for
clinical trial materials in Europe and Asia Pacific."
ABOUT PATHEON
Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of
contract development and manufacturing services to the global pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 300 of the world's leading pharmaceutical and
biotechnology companies. Patheon's services range from preclinical development
through commercial manufacturing of a full array of dosage forms including
parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative
technologies including single-use disposables, Liquid-Filled Hard Capsules and
a variety of modified release technologies.
Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon
can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(TM) programs can
accelerate early phase development project to clinical trials while minimizing
the consumption of valuable API. Patheon's integrated network strives to
ensure that customer products can be launched with confidence globally.
ABOUT OMNICARE CLINICAL RESEARCH
Headquartered in King of Prussia, PA, Omnicare Clinical Research provides
clinical development services to pharmaceutical, biotechnology, nutraceutical
and medical device companies through its office locations in 30 countries
worldwide. As a premier Phase I-IV contract research organization, Omnicare
Clinical Research features diverse therapeutic expertise and a comprehensive
scope of clinical service offerings. Additionally, the company is an industry
leader in geriatrics-focused drug studies. Omnicare Clinical Research focuses
on providing clients with a superior drug development experience through
strong project management, exceptional service and proactive solutions. The
company is a subsidiary of Omnicare, Inc., a leading provider of pharmacy
services to long-term care facilities and other chronic care settings
comprising nearly 1.4 million beds in 47 states (NYSE: OCR).
Caution Concerning Forward-Looking Statements
This news release may contain forward-looking statements which reflect
management's expectations regarding the Company's future growth of operations,
performance (both operational and financial) and business prospects and
opportunities. These statements are made in the context of the risks and
uncertainties that are outlined in the Company's public documents, which can
be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.
%SEDAR: 00001700E
